Resistance Exercise and Creatine in Colorectal Cancer - Trial NCT06420726
Access comprehensive clinical trial information for NCT06420726 through Pure Global AI's free database. This phase not specified trial is sponsored by University of South Carolina and is currently Recruiting. The study focuses on Colorectal Cancer. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of South Carolina
Timeline & Enrollment
N/A
Sep 01, 2023
Jul 22, 2025
Primary Outcome
Recruitment,Retention,Supplementation Adherence,Exercise Adherence
Summary
skeletal muscle mass and function, is prevalent in up to 60% of colorectal cancer patients.
 This condition arises from a combination of factors such as aging, inactivity, treatment side
 effects, malnutrition, tumor burden, and inflammation. Given this complexity, singular
 interventions may not be sufficient to address sarcopenia in this group.
 
 Creatine monohydrate, a compound vital for energy during exercise, has been extensively
 researched and proven safe and effective across various demographics, including older adults
 and clinical populations. Studies show that creatine enhances benefits from resistance
 training, indicating potential to counter muscle mass and function decline post-cancer
 treatment.
 
 This study aims to assess the feasibilty of combining creatine supplementation with
 resistance training versus resistance training alone in sarcopenic colorectal cancer
 survivors. A randomized controlled pilot trial will compare a 10-week program of resistance
 exercise plus creatine (EXSUPP) with resistance exercise alone (EXPLA), each with 20
 participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06420726
Non-Device Trial